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Abstract
Background. The vulnerability hypothesis suggests that impairments after remission of
depressive episodes reflect a pre-existing vulnerability, while the scar hypothesis proposes
that depression leaves residual impairments that confer risk of subsequent episodes. We pro-
spectively examined vulnerability and scar effects in mental and physical functioning in a rep-
resentative Dutch population sample.
Methods. Three waves were used from the Netherlands Mental Health Survey and Incidence
Study-2, a population-based study with a 6-years follow-up. Mental and physical functioning
were assessed with the Medical Outcomes Study Short Form (SF-36). Major depressive dis-
order (MDD) was assessed with the Composite International Diagnostic Interview 3.0.
Vulnerability effects were examined by comparing healthy controls (n = 2826) with indivi-
duals who developed a first-onset depressive episode during first follow-up but did not
have a lifetime diagnosis of MDD at baseline (n = 181). Scarring effects were examined by
comparing pre- and post-morbid functioning in individuals who developed a depressive epi-
sode after baseline that was remitted at the third wave (n = 108).
Results. Both mental (B =−5.4, S.E. = 0.9, p < 0.001) and physical functioning (B =−8.2, S.E. =
1.1, p < 0.001) at baseline were lower in individuals who developed a first depressive episode
after baseline compared with healthy controls. This effect was most pronounced in people
who developed a severe episode. No firm evidence of scarring in mental or physical function-
ing was found. In unadjusted analyses, physical functioning was still lowered post-morbidly
(B =−5.1, S.E. = 2.1, p = 0.014), but this effect disappeared in adjusted analyses.
Conclusions. Functional impairments after remission of depression seem to reflect a pre-
existing vulnerability rather than a scar.
Introduction
Major depressive disorder (MDD) is a prevalent disease (Kessler et al. 2005; De Graaf et al.
2012), characterized by a persistent depressed mood and/or marked loss of pleasure
(American Psychiatric Association, 2013). MDD is a highly recurrent disorder and risk of
recurrence is related to the number of previous episodes (Solomon et al. 2000; Kessing
et al. 2004). This observation stimulated the idea that depressive episodes leave more or less
permanent residual impairments or scars that confer risk of subsequent episodes; the ‘scar
hypothesis’ (Rohde et al. 1990; Burcusa & Iacono, 2007). Indeed, many studies comparing
remitted depressed patients with healthy controls have shown that the former differ in certain
ways from the latter (Just et al. 2001; Bhagwagar & Cowen, 2008; Paykel, 2008). Such studies,
however, cannot rule out the possibility that post-morbid impairments already existed before
the onset of the episode, predisposing people to depression. Thus, individuals with a history of
depression may already have had certain characteristics that made them vulnerable to recur-
rent depression beforehand. This is called the ‘vulnerability hypothesis’ (Just et al. 2001;
Christensen & Kessing, 2006; Sowislo & Orth, 2013) or ‘trait marker hypothesis’ (Rohde
et al. 1990).
To distinguish between pre-existing vulnerabilities and scars, prospective studies with pre-
and post-morbid data of first-onset depressed subjects are required (i.e. subjects with a first-
lifetime occurrence of an MDD episode). The few available prospective studies, most often
done in population-based samples, have addressed scarring in psychosocial functioning
(Burcusa & Iacono, 2007, review), cognitive functioning (Burcusa & Iacono, 2007; Allott
et al. 2016, reviews), self-esteem (Sowislo & Orth, 2013, review), personality (Christensen &
Kessing, 2006, review), and after stressful life events (Burcusa & Iacono, 2007, review).
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These reviews have shown that there is more evidence for the vul-
nerability hypothesis than for the scar hypothesis. There is slight
evidence in favor of scarring in neuroticism (Kendler et al. 1993;
Burcusa & Iacono, 2007) and some evidence that sensitization to
stressful life events occurs (Monroe & Harkness, 2005; Burcusa &
Iacono, 2007), but evidence for psychosocial or cognitive scars is
virtually absent.
A limitation of the few longitudinal population studies done
thus far is that in most studies the number of people who devel-
oped a depressive episode during the study follow-up was very
small, leaving limited power to detect vulnerability or scarring
effects. Further, it may be that scarring only occurs when depres-
sive episodes are severe, long-lasting, or recurrent. Ormel et al.
(2004a) indeed observed scarring effects in psychosocial disability
only in individuals with severe recurrent episodes, although they
could not replicate this regarding scars in neuroticism, depressive
coping, and self-esteem (Ormel et al. 2004b), and did not control
for possible confounders. Most longitudinal studies on scarring,
however, did not separately investigate severe or recurrent epi-
sodes. Further, most studies focus on mental scars; there are
hardly any studies that investigated physical functioning pre-
and post-morbidly.
We investigated vulnerability and scar effects in mental and
physical functioning among adults with a major depressive dis-
order in a large sample representative of the general Dutch popu-
lation. We used three waves from the Netherlands Mental Health
Survey and Incidence Study-2 (NEMESIS-2), a prospective epi-
demiological study with a 6-years follow-up. We specifically
focus on the questions: (1) whether levels of premorbid function-
ing of individuals who develop a first-onset depressive episode
differ from those of healthy controls (vulnerability effect); (2)
whether residual impairments in functioning remain after remis-
sion of the depressive episode (scar effect); (3) whether vulnerabil-
ity or scar effects are different for mental compared with physical
functioning; and (4) whether vulnerability or scar effects are dif-
ferent for recurrent v. first-onset episodes, and for episodes of dif-
ferent severity. We hypothesized that vulnerability but not scar
effects will be found in general, but that scarring will be detected
in the subgroup with recurrent or severe depression. Further, we
examined whether the results may be confounded by comorbid
disorders or by prodromal or residual symptom severity.
Methods
Participants
We used data from the first three waves of NEMESIS-2, a prospect-
ive epidemiological cohort study in the Dutch adult general popu-
lation (de Graaf et al. 2010). The inclusion criterion for this study
was age between 18 and 64 at the time of the baseline interview.
Insufficient fluency in Dutch was an exclusion criterion.
Participants were randomly selected by means of a multistage,
stratified sampling procedure, with one respondent being randomly
sampled from randomly selected households sampled from ran-
domly selected municipalities. In the baseline wave (T0), between
November 2007 and July 2009, 6646 individuals were assessed by
means of face-to-face interviews (response rate 65.1%). This sample
was reasonably representative of the Dutch general population,
though younger individuals were somewhat underrepresented (de
Graaf et al. 2010). During the second wave (T1), 3 years after T0,
5303 participants were interviewed again (response rate 80.4%).
In the third wave (T2), 3 years after T1, 4618 participants were
re-interviewed (response rate 87.8%). NEMESIS-2 was approved
by an independent Medical Ethics Committee and all participants
provided written informed consent. For more details about the
study design, see de Graaf et al. (2010).
Measures
The Medical Outcomes Study Short Form Health Survey (SF-36,
Ware & Sherbourne, 1992) was used to assess mental and physical
functioning at each wave. The SF-36 is a self-report questionnaire
consisting of 36 items and eight subscales which assess the level of
functioning during the previous 4 weeks (McHorney et al. 1994).
The scale is composed of 36 items, rated on Likert-type scales.
Item responses are converted to a scale ranging from 0 to 100,
with higher scores indicating better functioning. The scores are
averaged to create the subscale scores. The SF-36 has been widely
used and its psychometric properties are good (McHorney et al.
1993, 1994; Aaronson et al. 1998). We combined four of the
SF-36 subscales into a mental health component scale, namely
mental health, role limitations due to emotional problems,
social functioning, and vitality (Cronbach’s α = 0.78 at T0). The
other four SF-36 subscales were combined into a physical health
component scale, namely general health perceptions, physical
functioning, role limitations due to physical health problems,
and bodily pain (Cronbach’s α = 0.79 at T0). Earlier principal
component analyses on the SF-36 have provided support for the
validity of these two component scales (McHorney et al. 1993;
Sanson-Fisher & Perkins, 1998). Scores on these scales range
from 0 (poor) to 100 (good).
DSM-IV diagnoses were established with the Composite
International Diagnostic Interview (CIDI) version 3.0, a fully
structured lay-administered diagnostic interview (Kessler &
Üstün, 2004). At all three waves, the disorders assessed were
mood disorders (major depressive disorder, dysthymia, bipolar
disorder), anxiety disorders (generalized anxiety disorder, panic
disorder with or without agoraphobia, agoraphobia without
panic disorder, specific phobia, and social phobia), and substance
use disorders (alcohol/drug abuse and dependence). The CIDI 3.0
assesses these disorders with generally good validity in compari-
son with blinded clinical reappraisal interviews (Haro et al.
2006). At all waves, 12-month diagnoses were assessed. Lifetime
diagnoses were assessed at T0. At T1 and T2, an adapted CIDI
version was used with as timeframe the period between T0–T1
and T1–T2, respectively.
Healthy controls (n = 2826) were defined as participants who
did not have any lifetime diagnosis of a mood, anxiety, or substance
use disorder at T0, and who did not develop any within the T0–T1
interval (Table 1). MDD (n = 295) individuals were defined as par-
ticipants who did not have a 12-month diagnosis of MDD at T0
and who developed an MDD within the T0–T1 interval. The dis-
tinction between a first-onset (n = 181) and recurrent MDD (n =
114) was determined according to the absence or presence of a
CIDI lifetime diagnosis of MDD at T0. Severity of the MDD was
assessed at T1 in those who had a CIDI 12-month diagnosis of
MDD and was based on criteria used in previous studies
(Demyttenaere et al. 2004; Ten Have et al. 2013). Disorders were
classified as severe if participants reported severe impairments in
at least two areas of role functioning on the Sheehan Disability
Scales (SDS, Leon et al. 1997); as moderate in case of moderate
role impairment in any domain of the SDS; and the remaining
were classified as mild. The SDS is a self-report measure of disabil-
ity in four role domains (home, work, social, close relationships)
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and is incorporated in the CIDI 3.0. The scale has shown good reli-
ability and validity (Leon et al. 1997). It consists of four questions
assessing, on a scale from 0 to 10, the extent to which a particular
disorder interfered with activities in one of the four role domains
during the month in the past year when the disorder was most
severe. Note that this measure of severity is based on the impact
the disorder has on a person’s functioning rather than on symptom
severity.
Covariates
Covariates used in the analyses consisted of demographic and
clinical variables, and were chosen based on their presumed asso-
ciation with both predictor and outcome. Demographic variables
were assessed at baseline and included age, sex, and education.
Education was defined as either low (primary, basic vocational,
and low secondary education) or high (high secondary education,
higher professional education, and university). Clinical variables
included the presence of a comorbid anxiety disorder and the
presence of a somatic disorder. The presence of a comorbid anx-
iety disorder (yes/no) was defined as any 12-month anxiety dis-
order according to the CIDI. This was assessed at all three
waves. The presence of somatic disorders was also assessed at
all three waves and ‘any somatic disorder’ was considered present
if one or more of 17 chronic somatic disorders from a standard
checklist was reported and had been treated or monitored by a
medical doctor in the previous 12 months. These disorders
included the most common chronic somatic disorders such as
hypertension, chronic backache, rheumatoid disease, asthma,
and diabetes. Comparisons between self-reports of chronic som-
atic disorders and medical records show moderate to good con-
cordance (Baker et al. 2004; NCHS, 2004). Subthreshold
residual symptoms were assessed at T2 with the K10, a self-report
screening questionnaire with strong psychometric properties
assessing psychological distress in the depression-anxiety spec-
trum in the past 4 weeks with 10 items on a five-point scale
(Kessler et al. 2002; Donker et al. 2010). The K10 has proven to
be both reliable and valid (Kessler et al. 2002; Donker et al. 2010).
Statistical analysis
Vulnerability effect
To examine the presence of a vulnerability effect, we compared
the level of functioning at baseline (T0) between the healthy
controls (n = 2826) and participants who did not have a lifetime
diagnosis of MDD at T0 and who developed a first-onset MDD
between T0 and T1 (n = 181). Differences in demographic charac-
teristics between the healthy and MDD group were examined
using Chi-square tests for categorical variables and one-way
ANOVA for continuous variables. First, mental functioning and
physical functioning at T0 (thus prior to the development of
the depressive episode) were compared between the first-onset
MDD and the healthy group using linear regression analyses.
The analyses were subsequently adjusted for age, sex, and educa-
tion. The analyses on mental functioning were additionally
adjusted for 12-month comorbid anxiety disorders at baseline,
and the analyses on physical functioning were additionally
adjusted for 12-month somatic disorders at baseline. We also
examined whether the recurrent MDD subgroup (n = 114) dif-
fered from the HC group, and whether the first-onset and the
recurrent MDD subgroups differed from each other. We further
examined whether vulnerability effects were different for those
who developed a mild, v. a moderate, v. a severe first-onset
depressive episode. Because severity could only be assessed in
those who had a 12-month diagnosis at T1 (n = 118, of the
total of 181 in the first-onset MDD group), we restricted the ana-
lyses on severity subtype to these participants. Multiple tests were
conducted, with a maximum of nine tests for each outcome meas-
ure. To ensure that the cumulative type I error remained below
0.05, an effect was considered significant if the p value was
below 0.0056. A power analysis showed that with this adjusted
alpha level we still had a power of 0.99 to detect a difference
with a moderate effect size (d = 0.50) between the first-onset
MDD group and the HC group.
Scar effect
To assess the presence of a scar effect, we compared the level of
functioning prior to the onset of the depressive episode with
the level of functioning following remission of the depressive epi-
sode. We did so in participants without a 12-month MDD at T0,
who had a 12-month MDD at T1, and who had no 12-month
MDD at T2 (i.e. were remitted at T2). This sample consisted of
108 participants. We used the 12-month diagnosis at T1 (and
not the 3 years interval diagnosis at T1) to be able to assess the
severity of the disorder. To account for the repeated measure-
ments in the data, linear mixed models were used with mental
and physical functioning as dependent variables and dummy vari-
ables for time T1 and time T2 as independent variables (time T0





n = 181 n = 114 n = 2826 F/χ2 p
Age, mean (S.D.) 41.2 (12.0) 43.4 (11.8) 45.5 (12.4) 11.5 <0.001
Sex, % female (n) 55.3 (100) 76.3 (87) 54.4 (1538) 21.2 <0.001
Education, % high (n) 69.1 (125) 72.8 (83) 70.2 (1983) 0.5 0.79
Comorbid anxiety disorder at T0, % (n) 18.2 (33) 26.3 (30) 0 639.1 <0.001
Any somatic disorder at T0, % (n) 36.9 (66) 56.5 (61) 32.0 (892) 29.3 <0.001
F, F-value from analysis of variance test; χ2, Chi-square value from Chi-square test.
Post-hoc tests show that the difference in sex and somatic comorbidity is only significant for the recurrent subgroup versus HC comparison.
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being the reference category). The restricted maximum likelihood
was used as the estimation method and the Akaike Information
Criterion was used for model selection. First, we examined a
model with the dummy variables for time T1 and time T2 only.
For mental functioning this resulted in a model with a random
intercept, a random slope for time T2, and an independent
covariance structure for the random effects and the residuals.
For physical functioning, the same model without random slopes
was optimal.
Next, we adjusted the models for age, sex, and education, and
additionally for comorbid anxiety disorders (mental functioning
model) and somatic disorders (physical functioning model).
The latter variables were time-varying. When a scar effect was
present after remission, lower functioning scores would be
found at time T2 compared with time T0. A state effect would
be visible in worse functioning scores at time T1 compared
with T0. Finally, we examined the presence of a scar effect in spe-
cific subgroups (first-onset v. recurrent episode; mild v. moderate
v. severe episode), by adding the subgroup variable and the inter-
action between this variable and the time variables to the adjusted
model (two separate models). In view of the smaller sample size in
the scar analyses and the lower total number of tests, we adopted a
somewhat less conservative p value adjustment here (Leon, 2014),
using an α-level of 0.0167. A power analysis showed that with this
adjusted alpha level we still had a power of 0.92 to detect a differ-
ence with a moderate effect size in functioning before v. after the
depressive episode in the sample of 108 MDD patients.
Prodromal and residual symptoms
Vulnerability effects may be biased by prodromal symptoms,
because premorbid assessments done just before the onset of
the depressive episode may reflect prodromal symptomatology
(Ormel et al. 2004a). Scar effects, as estimated in the pre-post
comparison, may be biased by both prodromal and residual
symptoms; if the post-morbid assessment takes place just after
remission of the depressive episode, scarring effects may be over-
estimated due to the presence of residual symptoms. If the
premorbid assessment takes place just before the onset of the
depressive episode, scarring effects may be obscured due to the
presence of prodromal symptoms. To examine whether residual
symptoms may have biased the results on scarring, we checked
whether the type and severity subgroups differed with respect to
their K10 scores at T2 using one-way ANOVA. Because the K10
was only assessed at T2, not at T0, we examined whether pro-
dromal symptoms may have biased the results in an indirect
way, by comparing MDD participants with a depression onset
within 1 year after T0 v. those with a later onset in the T0–T1 per-
iod on mental and physical functioning.
Results
Baseline demographic and clinical characteristics of the 181 first-
onset and 114 recurrent MDD participants are presented in
Table 1 and compared with those of the 2826 healthy individuals.
Individuals in both MDD subgroups were on average younger and
more often suffered from a comorbid anxiety disorder at baseline
than healthy individuals. Individuals in the recurrent subgroup
were also more often female and more often suffered from a som-
atic disorder at baseline than healthy individuals.
Vulnerability effect
The regression models showed that mental functioning at T0,
before the depressive episode developed, was significantly lower
in the first-onset MDD group compared to the healthy group
(B =−7.8, S.E. = 0.8, p < 0.001). Adjusting the analyses for age,
sex, education, and anxiety comorbidity did not substantially
change these results (see Table 2). Physical functioning was also
significantly lower at baseline in the first-onset MDD group
than in the healthy group in unadjusted (B = −8.8, S.E. = 1.2, p <
0.001) and adjusted analyses (Table 2). Thus, in participants
who developed a first depressive episode after T0, both mental
and physical functioning were already impaired prior to the
onset of the depressive episode.
Table 2. Evaluating vulnerability effects; mental and physical functioning at T0 of participants who developed a 12-month major depressive disorder between T0
and T1 (first-onset and recurrent MDD) and healthy controls
MDD
Healthy controls Adjusted regression
Test statistic
First onset Recurrent
n = 181 n = 114 n = 2826
Mean (S.D.) Mean (S.D.) Mean (S.D.) B S.E. p
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Mental functioning at T0 was significantly lower also in the
recurrent MDD subgroup (n = 114) compared with the healthy
group (Table 2). The same was true for physical functioning.
Further, the recurrent subgroup showed lower mental functioning
than the first-onset subgroup (Table 2). The difference in physical
functioning between the recurrent and first-onset subgroups was
not significant.
Next, we examined whether the severity of the depressive epi-
sode influenced the results. Of the 118 first-onset participants in
which episode severity was assessed, 12 had a mild, 39 a mod-
erate, and 67 a severe depressive episode. Mental functioning
was significantly lower at T0 in the severe subgroup compared
with the healthy group (Table 3). The mild and moderate sub-
group did not differ significantly from the healthy group. The
severe subgroup also had lower mental functioning at T0 than
the moderate subgroup, while the difference between the severe
and mild subgroup showed a trend ( p = 0.010). The moderate
subgroup did not differ significantly from the mild subgroup.
Similar results were found for physical functioning, which was
also significantly lower at T0 only in the severe subgroup com-
pared with the healthy group (Table 3). The severe subgroup
also had lower physical functioning than the moderate subgroup,
while the difference between the severe and mild subgroup
showed a trend ( p = 0.011). The moderate subgroup did not dif-
fer significantly from the mild subgroup. Thus, those who devel-
oped the most severe depressive episode between T0 and T1 also
had the worst level of mental and physical functioning prior to
episode onset compared with those with less severe or no
episodes.
To test whether prodromal symptoms may have biased the
results, we examined whether first-onset participants whose
depressive episode started within 1 year after T0 (n = 87) differed
from participants with a later onset (n = 94) on baseline mental
and physical functioning. This was not the case (adjusted ana-
lyses; mental functioning, B =−0.3, S.E. = 2.1, p = 0.88; physical
functioning, B =−2.3, S.E. = 2.7, p = 0.40). Thus, the observed vul-
nerability effects in mental and physical functioning were not
likely to be reflections of prodromal symptoms.
Scar effect
The characteristics of the 108 MDD participants who had devel-
oped a 12-month diagnosis of depression at T1 and were remitted
at T2 are described in Table 4. Mean mental functioning in this
group was lower at T1 than at T0, prior to the development of
the depressive episode, and returned to premorbid levels following
remission at T2 (see Table 5). The linear mixed models showed a
state effect but no scar effect with regard to mental functioning,
both in unadjusted (time T1, B = −15.1, S.E. 2.4, p < 0.001; time
T2, B =−2.3, S.E. 1.8, p = 0.18) and adjusted analyses (Table 5).
The random slope for time T2 was significant (S.D. = 17.3, 95%
CI 13.7–21.7), which implies that there was large heterogeneity
in the scarring effect. Physical functioning was higher at T0
than at T1 and T2. In the unadjusted model for physical function-
ing, both the state effect (time T1, B =−5.7, S.E. = 2.1, p = 0.006)
and the scar effect (time T2, B =−5.1, S.E. = 2.1, p = 0.014) showed
significance. In the adjusted analyses, neither the state nor the
scar effect was significant (Table 5).
Table 3. Evaluating vulnerability effects in different severity groups; mental and physical functioning at T0 of participants who developed a first-onset 12-month
major depressive disorder between T0 and T1 (mild, moderate, and severe MDD) and healthy controls
First-onset MDD
Healthy controls Adjusted regression
Test statistic
Mild Moderate Severe
n = 12 n = 39 n = 67 n = 2826
Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.) B S.E. p














Regression analyses on mental functioning adjusted for age, sex, education, and any anxiety disorder; regression analyses on physical functioning adjusted for age, sex, education, and
somatic disorders.
Severity refers to role functioning impairment due to the depressive episode, as assessed by the Sheehan Disability Scales.
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Subsequently, we examined whether any scar effects were dif-
ferent for specific subgroups, according to the type of disorder
(first-onset, n = 70 v. recurrent, n = 38) and disorder severity
(mild, n = 10 v. moderate, n = 41 v. severe, n = 57). In both the
mental functioning and the physical functioning model, neither
of the interaction terms were significant, indicating that scar
effects were not more pronounced in individuals with recurrent
of more severe episodes (results not shown).
Next, we examined whether scarring effects were different in
participants with an onset within one year after T0 (n = 35) and
participants with a later onset (n = 73). Also in these models,
no significant interaction effects were observed. Finally, we exam-
ined whether residual symptoms levels (K10 scores) were different
for those with a first-onset v. a recurrent episode, which was not
the case [F(1106) = 0.37, p = 0.54]. Neither were K10 scores differ-
ent for subgroups with different disorder severity [F(2105) = 0.43, p
= 0.52]. So, the results were not likely influenced by prodromal or
residual symptoms.
Discussion
The present three-wave population-based study was aimed to dis-
tinguish between pre-existing vulnerability and scar effects in
mental and physical functioning after the experience of an epi-
sode of major depressive disorder. We did so by comparing indi-
viduals who developed a first-onset depressive episode during
follow-up with healthy controls (vulnerability effect), and with
themselves after remission of the depressive episode (scar effect).
The results provide more support for the vulnerability than the
scar hypothesis: both mental and physical functioning were
already impaired prior to the onset of the depressive episode,
and no firm evidence of scarring after remission was found.
Subgroup analyses showed that the vulnerability effects mainly
applied to persons with a severe depressive episode (‘severe’ in
terms of role functioning impairment).
The results are congruent with those of previous studies done
on this topic, the majority of which showed vulnerability but not
scar effects on diverse outcomes (for reviews, see Christensen &
Kessing, 2006; Burcusa & Iacono, 2007; Sowislo & Orth, 2013;
Allott et al. 2016). Notably, studies that did find effects congruent
with the scar hypothesis most often had a design in which indi-
viduals with remitted depression were compared with healthy
controls, a design in which vulnerability and scar effects are con-
founded (Just et al. 2001). Possibly, much of the impairments
observed in remitted patients can be accounted for by pre-existing
characteristics that predispose these people to depression (vulner-
ability) or are due to common causes. Similarly, the often-made
assertion that risk of recurrence increases with every further epi-
sode (Kessing et al. 2004), which has often been considered as
support for the scar hypothesis, may actually be explained by pre-
existing between-subjects differences: people with more previous
episodes than other people may have a higher risk of recurrence
just because they were vulnerable to recurrent episodes right
from the start. Also in our study persons with recurrent MDD
showed lower mental functioning before the onset of the episode
than healthy persons, and their functioning was also lower than
persons with first-onset depression. This may thus reflect a pre-
existing differential vulnerability. Alternatively, the latter differ-
ence could be a reflection of scarring that occurred earlier in
life. However, our subsequent analyses did not show evidence of
scarring.
Although we did not find firm evidence for scarring in our
study (only a scarring effect in physical functioning in unadjusted
analyses), there was substantial heterogeneity in the degree to
which mental functioning was still lowered after remission of
the depressive episode. This heterogeneity could not be explained
by type, severity, or timing of the depressive episode. There are
not many studies who examined such subgroups. Ormel et al.
(2004a) did so, and found some scarring in psychosocial func-
tioning in individuals with severe recurrent episodes, in
unadjusted analyses. In our unadjusted analyses, we found signifi-
cant scarring in physical functioning, but this effect disappeared
Table 4. Characteristics of participants who developed a 12-month major
depressive disorder between T0 and T1 and were remitted at T2, as used to
examine a scar effect
n = 108
Age, mean (S.D.) 42.3 (12.2)
Sex, % female (n) 65.7 (71)
Education, % high (n) 71.3 (77)
Comorbid anxiety disorder at T1, % (n) 29.6 (32)
Any somatic disorder at T1, % (n) 52.8 (57)
Table 5. Evaluating scar effects; mental and physical functioning of participants who developed a 12-month major depressive disorder between T0 and T1 and were
remitted at T2
T0 T1 T2 Adjusted regression
Test statistic
n = 108 n = 108 n = 108
Mean (S.D.) Mean (S.D.) Mean (S.D.) B S.E. p
Mental functioning 79.6 (15.9) 63.8 (25.0) 77.3 (16.4)
−14.0 2.4 <0.001
−2.1 1.7 0.19
Physical functioning 77.9 (20.2) 72.2 (23.6) 72.8 (23.6)
−2.8 2.0 0.17
−2.3 2.0 0.26
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after adjustment, which suggests confounding by the presence of
somatic disorders. An alternative explanation for this finding
might be that the presence of MDD increases the likelihood of
developing a somatic disorder. The high percentage of people
with recurrent MDD having comorbid somatic disorders
(Tables 1 and 4) is remarkable in this respect. If this alternative
explanation would be true, we might have over-adjusted by
using somatic disorders as a confounder, since this somatic dis-
order may be considered a scar. These reflections point to the
more general problem that it is always hard to decide which vari-
ables should be used as potential confounders. In a recent study
on scarring after remission of an anxiety disorder (Schopman
et al. 2017), scarring was found in mental but not physical func-
tioning in the subgroup with recurrent anxiety, also after adjust-
ment. Power issues are also prevailing here, because subgroups
were often very small, also in our study. Further, it might be
that any scarring already occurred before T0 in those with previ-
ous episodes, limiting further scarring. Thus, although it may still
be too early to discard the idea that scarring occurs altogether –
maybe scarring does occur, but in a subtle way (Wichers et al.
2010), in subgroups we did not investigate, or in outcome measures
we did not investigate (Burcusa & Iacono, 2007; Bhagwagar &
Cowen, 2008) – our study suggests there is no robust scarring effect.
In contrast to the scarring effects, the vulnerability effects
observed in the present study were robust and substantial.
Effect sizes, calculated by dividing the adjusted estimated mean
difference between the groups by the pooled standard deviation
(Cohen, 1988, p.44), were 0.43 for mental functioning and 0.46
for physical functioning (first-onset MDD group), and especially
large in the severe subgroup (0.66 for mental functioning; 0.69 for
physical functioning). These effect sizes are slightly larger than
those found for the average prospective association between neur-
oticism and depression, one of the most notorious risk factors for
depression (Jeronimus et al. 2016). Functional limitations follow-
ing remission from depression thus presumably reflect pre-
existing vulnerabilities rather than scars. This may have clinical
implications, as people with impaired functioning in either men-
tal, social, or physical areas are at increased risk of (recurrence of)
depression (Lewinsohn et al. 1998; Oldehinkel et al. 2001;
Solomon et al. 2004; Conradi et al. 2008), and these impairments
are not merely reducible to subthreshold symptoms (Spijker et al.
2007). Treatment and prevention strategies may be thus improved
by targeting patients’ level of functioning. Solely focusing on
symptom reduction may be ‘trying to dry out a flooded room
without turning off the taps’, if the underlying vulnerability is
not addressed.
A vulnerability perspective of depression may also have impli-
cations for how we conceive this disorder. Depression is, even
though operationalized as episodic, seldom an isolated event,
but rather an expression of an underlying vulnerability. Many per-
sons suffering from a current depressive episode have had other
mental or somatic disorders in their past, which may be indicative
of this vulnerability. Previous work on lifetime comorbidity of
mental disorders has shown that disorders tend to cluster in
large domains of psychopathology, such as internalizing and
externalizing disorders (Kessler et al. 2011a, b). Depression has
a median age of onset around 30 (Bromet et al. 2011), while
some of the other disorders in the internalizing domain, such
as specific phobia (age 8) or social phobia (age 14), have a consid-
erably earlier onset (Lijster et al. 2017; Wardenaar et al. 2017).
Perhaps such disorders with an early age of onset can be seen
as markers of an underlying internalizing vulnerability that
eventually leads to disorders such as depression and generalized
anxiety disorder. Viewing psychopathology from a lifespan per-
spective opens the way of preventing depression in such targeted
subpopulations. It should also be noted that although disorders
are typically defined as discrete, the underlying vulnerability
may well be continuous (Ten Have et al. 2016).
Limitations of the present study include the self-report nature
of our measures and the fact that they were assessed retrospect-
ively, which might have induced some mood-related reporting
bias. However, functioning was assessed prior to onset and 1
year after remission of the depression, presumably reducing this
bias to acceptable levels. Further, we examined whether the timing
of the onset (as a proxy for prodromal symptom severity) and
residual symptom severity influenced the results, which was not
the case. Another limitation may be that we used the Sheehan dis-
ability scale as a measure of depression severity, which may poten-
tially overlap with our outcome measures. However, the SDS
assesses disability due to the presence of the disorder, whereas
the SF-36 assesses mental and physical functioning in general.
A further limitation is that we did not assess prodromal symptom
severity directly, but instead used the timing of the onset, because
the K10 was not assessed at T0.
To conclude, this study suggests that limitations in mental and
physical functioning following remission of depression reflect a
pre-existing vulnerability rather than a scar. Depressive disorders
might be conceived as life-stage-dependent manifestations of an
underlying internalizing vulnerability dimension. A lifespan per-
spective of psychopathology opens the way of prevention strat-
egies targeting this vulnerability early in life.
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